HANK & LIN'S GROUP
The past is prologue and the future is scintillating
1.
Radiolabeling optimization and preclinical evaluation of the new PSMA imaging agent [(18)F]AlF-P16-093. Bioconjug Chem. 2021;32:1017–26.
2.
- First-in-human study of PSMA-targeting agent,[18F] AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients. EJNMMI(2024): 1-10.
- “Determining the optimal pharmacokinetic modelling and simplified quantification method of [18F]AlF-P16-093 for patients with primary prostate cancer (PPCa)”.European Journal of Nuclear Medicine and Molecular Imaging(2024): 1-10.
3.
EJNMMI radiopharm. chem.9, 15 (2024).
